Publications
Publications
- April 6, 2022
- NEJM.org
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
Abstract
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a regulatory or disruptive business fix is needed to bring down insulin prices. I describe one promising fix on the horizon: the announcement by a nonprofit firm, CivicaRx, to manufacture and sell its own interchangeable biosimilars, bypassing the traditional supply chain.
Keywords
Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Citation
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." NEJM.org (April 6, 2022).